SBI Okasan Asset Management Co.Ltd. Takes Position in Mirum Pharmaceuticals, Inc. $MIRM

SBI Okasan Asset Management Co.Ltd. acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 16,000 shares of the company’s stock, valued at approximately $1,283,000.

Other hedge funds also recently modified their holdings of the company. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $30,000. MCF Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Comerica Bank increased its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $41,000.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. TD Cowen boosted their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Citizens Jmp restated a “market outperform” rating and set a $132.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $137.08.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 7,287 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the sale, the insider directly owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This represents a 27.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Eric Bjerkholt sold 7,287 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the sale, the chief financial officer directly owned 49,788 shares in the company, valued at approximately $4,579,500.24. This trade represents a 12.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 76,806 shares of company stock worth $7,064,616 in the last ninety days. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $99.60 on Friday. The firm has a market capitalization of $6.07 billion, a PE ratio of -7.32 and a beta of 0.52. The firm has a fifty day simple moving average of $96.70 and a two-hundred day simple moving average of $89.36. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12 month low of $43.30 and a 12 month high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.30) earnings per share. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.11 EPS for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.